Fisetin Senolytic Research Guide: Dosage, Timing & Senescent Cell Clearance Protocol

Complete research guide to fisetin as a senolytic agent — flavonoid mechanism, comparison with dasatinib/quercetin, 20 mg/kg pulsed research dosing, 500–1500 mg human protocols, 2-day pulse timing, bioavailability challenges, and liposomal fisetin.

TL;DR

• Fisetin is a naturally occurring flavonoid with senolytic activity — it selectively clears senescent cells by inhibiting their pro-survival signaling pathways
• Animal research uses ~20 mg/kg in 2-day pulse protocols; human research protocols typically use 500–1500 mg over 2 consecutive days, repeated monthly
• Standard oral fisetin bioavailability is poor (<10%); fat co-administration or liposomal formulations significantly improve absorption
• Compared to dasatinib/quercetin, fisetin shows comparable or superior senolytic potency in some tissue models with a more favorable safety profile

Disclaimer: For educational and research purposes only — not medical advice.

Fisetin (3,3',4',7-tetrahydroxyflavone) is a naturally occurring flavonoid found in many fruits and vegetables, with particularly high concentrations in strawberries (~160 mcg/g), apples, persimmons, lotus root, and onions. While dietary fisetin intake has attracted attention for general antioxidant and anti-inflammatory properties, the compound rose to prominence in longevity research with the publication of a 2018 study in EBioMedicine by Yousefzadeh et al. (Mayo Clinic) demonstrating that fisetin was the most potent senolytic among 10 flavonoids tested — a finding that positioned it as a potential key tool in the emerging senolytic research field.

Senolytic Mechanism: BCL-2 Inhibition and PI3K/AKT Pathway

Cellular senescence is a state entered by cells that have experienced replication stress, DNA damage, oncogene activation, or other forms of cellular stress. Senescent cells are characterized by:

• Irreversible cell cycle arrest (typically via p21 and p16/INK4a pathways)
• Resistance to apoptosis (programmed cell death) via upregulation of BCL-2 family anti-apoptotic proteins
• Active secretion of inflammatory mediators (SASP: IL-6, IL-8, MCP-1, MMPs, growth factors)
• Altered metabolism and epigenetic state

The accumulation of senescent cells with age is thought to drive multiple hallmarks of aging and age-related diseases through chronic SASP-mediated tissue inflammation and dysfunction. Senolytics specifically target the pro-survival pathways that senescent cells rely on, tipping them toward apoptosis while leaving non-senescent cells largely unaffected (since non-senescent cells do not rely on the same survival pathways to the same degree).

Fisetin's senolytic mechanisms:

1. BCL-2/BCL-xL inhibition: Fisetin inhibits BCL-2 family anti-apoptotic proteins that are upregulated in senescent cells, reducing their resistance to apoptotic signals. This is the primary senolytic mechanism, similar to dasatinib's mechanism (though dasatinib works via tyrosine kinase inhibition that ultimately converges on the same survival pathways).

2. PI3K/AKT inhibition: Fisetin inhibits the PI3K/AKT/mTOR pathway, a critical pro-survival signaling cascade that many senescent cells depend on. Inhibiting this pathway promotes apoptosis selectively in senescent cells because they are more dependent on AKT survival signaling than normal cells.

3. p53/p21 pathway modulation: Fisetin appears to modulate p53-dependent apoptotic pathways in a manner that preferentially affects senescent cells, though this mechanism is less well characterized than the BCL-2 and PI3K pathways.

4. Anti-SASP activity: Beyond eliminating senescent cells, fisetin also reduces SASP output from surviving senescent cells — a dual mechanism that addresses both the cellular accumulation and the inflammatory secretion problems simultaneously.

Comparison with Dasatinib/Quercetin (D+Q)

The dasatinib/quercetin combination (D+Q) is the most extensively studied senolytic protocol, serving as the reference standard against which other senolytics are compared. Dasatinib is an FDA-approved cancer drug (BCR-ABL/Src kinase inhibitor) repurposed as a senolytic, while quercetin is a naturally occurring flavonoid with PI3K/AKT inhibitory activity.

A 2018 paper specifically comparing multiple flavonoids against the D+Q benchmark found that fisetin outperformed quercetin as a standalone senolytic in multiple cell types and approached dasatinib's potency in some assays. In brain tissue models, fisetin showed particular potency — relevant for neurodegenerative aging research.

Research Dosing: Animal to Human Translation

Animal Research Dosing: The landmark Yousefzadeh et al. (2018) study used fisetin at approximately 500 mg/kg/day in mouse chow for aging mice — a long-term dietary administration study. The subsequent protocol work established 20 mg/kg as a relevant acute senolytic dose for pulse administration studies. In aged mice, this dose produced significant reductions in senescent cell burden (measured by p16, p21, and SA-β-gal markers) across multiple tissues.

Human Dose Estimation: The 20 mg/kg mouse dose does not translate directly to humans using simple body weight scaling. Using the FDA's body surface area allometric scaling (dividing by the mouse-to-human Km factor of approximately 12):

• Mouse dose: 20 mg/kg
• Human equivalent dose: ~1.6 mg/kg
• For a 70 kg individual: ~112 mg (allometric equivalent)

However, given fisetin's very poor oral bioavailability and the empirical data from early human research, most research protocols have used substantially higher oral doses (500–1500 mg) to compensate for incomplete absorption and first-pass metabolism.

Current Human Research Protocol (SToMP-AD and similar):

• Dose: 1000–1500 mg/day for 2 consecutive days
• Frequency: Monthly pulse (every 28–30 days)
• Administration: With a fat-containing meal to maximize absorption
• Duration: 6–12 months in ongoing studies

Bioavailability: The Core Challenge

Fisetin's utility as a research compound is significantly constrained by its poor oral bioavailability, which results from two compounding problems:

1. Lipophilicity: Fisetin is highly fat-soluble, meaning it does not dissolve well in the aqueous GI environment. Poorly soluble compounds are incompletely released from solid dosage forms and incompletely absorbed from the GI lumen.

2. First-pass metabolism: Absorbed fisetin undergoes rapid conjugation in the intestinal epithelium and liver (glucuronidation, sulfation, methylation), producing metabolites that may retain some but not full activity, and reducing plasma concentrations of the parent compound.

Strategies to improve bioavailability:

• Fat co-administration: Taking fisetin with a high-fat meal increases absorption by facilitating dissolution and lymphatic transport. This is the simplest and most accessible approach and can meaningfully increase plasma concentrations.

• Liposomal fisetin: Phospholipid liposome encapsulation of fisetin protects it from GI enzymatic degradation and facilitates direct cellular uptake. Liposomal formulations have shown substantially higher plasma Cmax and AUC values compared to equivalent doses of standard fisetin in preliminary pharmacokinetic studies.

• Cyclodextrin complexation: Forming inclusion complexes of fisetin with beta-cyclodextrin improves aqueous solubility, addressing the dissolution limitation without requiring lipid carriers.

• Micronized / nanoparticle fisetin: Reducing particle size to the micron or nano range increases surface area for dissolution, improving absorption.

For longevity research purposes, the practical recommendation is to use liposomal fisetin formulations or to administer standard fisetin with a fat-containing meal during the 2-day pulse protocol.

Pulse Protocol Design

The 2-day pulse protocol reflects important considerations about senolytic biology:

• Senescent cells accumulate over weeks to months; a single clearance event does not require daily maintenance
• The recovery period between pulses allows normal tissue responses to proceed without ongoing senolytic pressure
• Monthly pulsing roughly corresponds to the rate at which senescent cells re-accumulate after clearance (based on p16/p21 biomarker re-elevation data in animal models)
• Longer inter-pulse intervals (quarterly) are also used in some research designs, particularly for older subjects where senescent cell burden is higher and clearance may take longer to complete

Sample Monthly Pulse Protocol (research framework):

• Days 1–2: Fisetin 500–750 mg (2x daily with high-fat meals, morning and evening)
• Days 3–28: No fisetin
• Day 29: Repeat cycle

Biomarker monitoring in research protocols typically includes: circulating senescence-associated secretory phenotype markers (IL-6, IL-8, MCP-1 in plasma), skin punch biopsy for p16/p21 expression, and functional assessments of mobility, grip strength, and cognitive performance.

Frequently Asked Questions

Q: Is there any evidence from human clinical trials yet? A: The SToMP-AD trial (Senolytic Therapy to Modulate the Progression of Alzheimer's Disease) using fisetin in early Alzheimer's patients is ongoing and represents the most advanced human senolytic trial with fisetin. Early-phase safety and tolerability data from this and related trials have been generally favorable, with no significant adverse events reported at 1000–1500 mg pulse doses. Efficacy data from these trials is pending.

Q: Can fisetin be stacked with quercetin or other senolytics? A: Fisetin and quercetin share overlapping mechanisms (both inhibit PI3K/AKT), so their combination may not provide purely additive senolytic effects. The D+Q protocol uses quercetin to complement dasatinib's tyrosine kinase inhibition, which is mechanistically distinct. Combining fisetin with dasatinib (mechanistically complementary) has more theoretical rationale, but this combination has not been formally studied and dasatinib's significant side effect profile warrants caution.

Use the Dosage Calculator [→ Link to /calculators/dosage]

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions